Mike Havrilla submits:Abbott Labs (NYSE:ABT) is poised to become the top pharmaceutical company in India, following its acquisition of Piramal's healthcare solutions business. The deal follows a collaboration announced last week between Abbott and India-based Zydus Cadila. Abbott also announced the establishment of a stand-alone established products division which accounts for over $5 billion in sales.
Analytical Chemist submits:Johnson & Johnson (JNJ) and Abbott Labs (ABT) are both large, diversified pharmaceutical and health care companies. While both have impressive records of sales, earnings, and dividend increases, Abbott Labs is a much better investment.
Jason Chew submits: It seems not a day goes by without talk of an innovation crisis in the pharmaceutical industry. On, October 25, the German consultancy, Roland Berger, released an article titled “Fight of Flight” stating 65% of companies surveyed believe that the pharmaceutical industry is facing a strategic crisis. As the patent cliff nears, it appears the majority of Big Pharmas have taken to the “flight” path.
Abbott Labs' (ABT) split into two separately trading companies: one, Abbott Labs, with diversified medical products, and the other, AbbVie (ABBV), with research-based proprietary pharmaceuticals, will be effective from today, on Jan 2., and AbbVie will begin trading today.
By Peter Maciejewski:Abbott Labs (ABT) plans to split into two companies by the end of 2012. There will be the proprietary pharmaceutical business with $17.4 billion in annual revenue and the other businesses of nutritional products, diagnostics established pharmaceuticals, medical devices (vascular care, diabetes care, medical optics and animal health) with $21.5 billion of annual revenue.